All In Biotech

Drug Trial Radar · NCT01795859

First Time Use of SD-809 in Huntington Disease

A Randomized Double-Blind, Placebo-Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease

Last checked: Nov 20, 2026Latest source record: Sep 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

90

Actual

Start

Aug 5, 2013

Primary completion

Dec 5, 2014

Study completion Dec 5, 2014

Sponsor

Sponsor type
Industry
First posted
Feb 21, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether SD-809 tablets are effective in the treatment of chorea associated with Huntington's Disease.

Conditions

  • Chorea

Interventions

  • SD-809Drug

    SD-809 tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white).

  • PlaceboDrug

    Placebo tablets are identical in appearance to SD-809 tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline (Average of Screening and Day 0) in the Average TMC Scores From Weeks 9 & 12Time frame: Screening, Day 0, Weeks 9, 12

Locations

43 sites in 3 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 057

    Birmingham, Alabama

  • Teva Investigational Site 038

    Phoenix, Arizona

  • Teva Investigational Site 298

    Fayetteville, Arkansas

  • Teva Investigational Site 050

    Los Angeles, California

  • Teva Investigational Site 052

    Englewood, Colorado

  • Teva Investigational Site 333

    Washington D.C., District of Columbia

  • Teva Investigational Site 196

    Boca Raton, Florida

  • Teva Investigational Site 160

    Gainesville, Florida

  • Teva Investigational Site 014

    Miami, Florida

  • Teva Investigational Site 032

    Atlanta, Georgia

  • Teva Investigational Site 045

    Indianapolis, Indiana

  • Teva Investigational Site 024

    Iowa City, Iowa

  • Teva Investigational Site 029

    Kansas City, Kansas

  • Teva Investigational Site 083

    Wichita, Kansas

  • Teva Investigational Site 087

    Louisville, Kentucky

  • Teva Investigational Site 028

    Baltimore, Maryland

  • Teva Investigational Site 040

    Boston, Massachusetts

  • Teva Investigational Site 027

    St Louis, Missouri

  • Teva Investigational Site 194

    Las Vegas, Nevada

  • Teva Investigational Site 328

    Camden, New Jersey

  • Teva Investigational Site 026

    New Brunswick, New Jersey

  • Teva Investigational Site 037

    Albany, New York

  • Teva Investigational Site 002

    New York, New York

  • Teva Investigational Site 342

    Patchogue, New York

  • Teva Investigational Site 119

    Durham, North Carolina

  • Teva Investigational Site 089

    Cincinnati, Ohio

  • Teva Investigational Site 020

    Columbus, Ohio

  • Teva Investigational Site 093

    Toledo, Ohio

  • Teva Investigational Site 341

    Tulsa, Oklahoma

  • Teva Investigational Site 031

    Nashville, Tennessee

  • Teva Investigational Site 007

    Houston, Texas

  • Teva Investigational Site 199

    Houston, Texas

  • Teva Investigational Site 100

    Salt Lake City, Utah

  • Teva Investigational Site 137

    Burlington, Vermont

  • Teva Investigational Site 220

    Kirkland, Washington

  • Teva Investigational Site 096

    Seattle, Washington

  • Teva Investigational Site 104

    Milwaukee, Wisconsin

  • Teva Investigational Site 144

    Kew Vic, Australia

  • Teva Investigational Site 054

    Sydney, Australia

  • Teva Investigational Site 098

    Montreal, Canada

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.